TriHealth invests $10M in adoption of IBM Watson Health

TriHealth, a Cincinnati-based health system, has announced a $10 million investment to implement the IBM Watson Health’s Enterprise Imaging Portfolio.

Using IBM’s portfolio, TriHealth aims to update its picture archiving and communication system (PACS) infrastructure to take advantage of artificial intelligence (AI) and applications for medical imaging.  The overall goal at TriHealth was to develop a system of interoperability. With IBM’s Watson, radiologists can go through the workflow of storage and management of image data on their electronic health record (EHR) system.

“We are excited to establish this valuable collaboration with IBM Watson Health for our enterprise imaging project,” said Frank Schlueter, MD, System Chief of Radiology for TriHealth. “I believe this advanced imaging technology will significantly improve the workflow of radiology and other image intensive specialties, enhancing our physicians’ ability to diagnose and treat patients.” 

The interoperability gained through the Watson Health Imaging will also be accompanied by the adoption of IBM Watson Imaging Clinical Review, which analyzed EHR data to provide accurate and coordinated care decision support.

“Our goal is to provide our physicians with a tool that delivers data and insight that helps optimize efficiency and quality in the care they deliver to patients,” said John Ward, TriHealth’s Senior Vice-President and Chief Information Officer. “After thoroughly reviewing a number of technologies, we chose Watson Health Imaging because of its advanced technology and architecture designed for the future of imaging, including the onset of Artificial Intelligence in the industry.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.